Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy
Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy
复制标题
DOI：
10.2217/nnm-2016-0062
复制
发表时间：
2016-08-01
期刊：
影响因子：
5.5
通讯作者：
Prise, Kevin M.
中科院分区：
文献类型：
--
作者：
Butterworth, Karl T.;Nicol, James R.;Prise, Kevin M.
金纳米粒子在癌症诊断和治疗中引起了极大的兴趣。在此，我们评估了二硫代二亚乙基三胺五乙酸（DTDTPA）缀合的金纳米颗粒（Au@DTDTPA）用于前列腺癌的CT对比增强和放射增敏的治疗诊断潜力。材料与方法：体外实验测定Au@DTDTPA的摄取、细胞毒性、放射增敏潜力和DNA损伤概况。使用人PC 3异种移植肿瘤模型来确定体内CT增强和辐射调节作用。结果：与仅辐射相比，暴露于纳米颗粒和辐射的细胞观察到存活率的显著额外降低。Au@DTDTPA产生10%的CT增强，并且与仅辐射相比，肿瘤生长延迟从16.9天显著延长至38.3天。结论：这项研究证明了Au@DTDTPA增强CT图像对比度的潜力，同时增加了前列腺肿瘤的放射敏感性。
Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer. Materials & methods: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing potential and DNA damage profiles. Human PC3 xenograft tumor models were used to determine CT enhancement and radiation modulating effects in vivo. Results: Cells exposed to nanoparticles and radiation observed significant additional reduction in survival compared with radiation only. Au@DTDTPA produced a CT enhancement of 10% and a significant extension in tumor growth delay from 16.9 days to 38.3 compared with radiation only. Conclusion: This study demonstrates the potential of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the radiosensitivity of prostate tumors.